A practical reference on NR1D1: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-17. Anything still debated is marked as such rather than presented as settled.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Growth that might also influence this would be large increases or drops in bodyweight/size due to fluctuations of fat (liposuction, rapid fat loss or gain) and/or muscle content (bodybuilding, anabolic steroids, catabolisis/starvation). It can also occur in those that gain new levels of flexibility, stretching, and contortion. A limb's being in a new range of motion never experienced (or at least, not for a long time since youth perhaps) can disrupt one's sense of location of that limb. Possible experiences include suddenly feeling that feet or legs are missing from one's mental self-image; needing to look down at one's limbs to be sure they are still there; and falling down while walking, especially when attention is focused upon something other than the act of walking.
The king brown snake (Pseudechis australis) or mulga snake is the largest species of venomous snake in Australia. The venom of this snake is relatively weak compared to many other Australian species. The LD50 is 2.38 mg/kg subcutaneous. However, these snakes can deliver large amounts of venom when they bite, compensating for the lower venom potency. Average venom yield is 180 mg and they have a maximum yield of 600 mg. The venom of this species contains potent myotoxins and anticoagulants, that can inhibit blood clotting. The neurotoxic components are weak. This snake can cause severe envenomation of humans. They are a moderately common cause of snakebites and uncommonly to rarely cause snakebite deaths in Australia at present. Envenomation can cause anticoagulation coagulopathy, kidney damage or kidney failure. They do not cause significant neurotoxic paralysis (muscle weakness, respiratory failure), though rarely they may cause ptosis (drooping of the upper eyelids). Bites can also cause myolysis (rhabdomyolysis, muscle damage) which can be very severe and is the major effect of bites. Rate of envenomation is 40–60%, while untreated mortality rate is 30–40%.
=== Video games === Major Force appears as a boss in DC Universe Online, voiced by Alexander Brandon. This version works for Amanda Waller. Major Force appears as a character summon in Scribblenauts Unmasked: A DC Comics Adventure.
Sources: en.wikipedia.org
=== Keratinization of sulcular epithelium === Although the inherent nature of the sulcular epithelium is non-keratinised, studies have discovered the potentiality of sulcular epithelium to keratinise under certain environmental conditions. It was shown that when exposed to the environment of the gingival surface, the sulcular epithelium develops into a keratinised squamous epithelium similar to that on the regular outer surface of the gingiva.
The Cherokee Freedmen, descendants of African American slaves owned by citizens of the Cherokee Nation during the Antebellum Period, were first guaranteed Cherokee citizenship under a new treaty made in 1866 with the United States. This was in the wake of the American Civil War, when the US emancipated slaves by passing a constitutional amendment granting freedmen citizenship in the United States. After the war the US government required that the Cherokee Nation, which under pressure had briefly allied with the Confederate States of America, end slavery and grant full citizenship to Freedmen living within their nation. Those who left could become United States citizens. However, despite "the promises of the 1866 treaty, the freedmen were never fully accepted as citizens of the Cherokee Nation" during the 19th and 20th centuries. In practice, enrollment in the Cherokee Nation rolls was often strongly influenced by race. During creation of the Dawes Rolls prior to allotment of tribal communal lands to households, many Freedmen and Afro-Cherokees were listed separately from Cherokee by blood, regardless of their ancestry or culture. As a result, they did not receive land allotments and later were for a time excluded from tribal membership.
== Modern hue rendering == True Tyrian purple, like most high-chroma pigments, cannot be accurately rendered on a standard RGB computer monitor. Ancient reports are also not entirely consistent, but these swatches give a rough indication of the likely range in which it appeared: _________ _________ The lower one is the sRGB colour #990024, intended for viewing on an output device with a gamma of 2.2. It is a representation of RHS colour code 66A, which has been equated to "Tyrian red", a term which is often used as a synonym for Tyrian purple.
Sources: en.wikipedia.org
== Prognosis == SJS (with less than 10% of body surface area involved) has a mortality rate of around 5%. The mortality for toxic epidermal necrolysis (TEN) is 30–40%. The risk for death can be estimated using the SCORTEN scale, which takes a number of prognostic indicators into account. It is helpful to calculate a SCORTEN within the first 3 days of hospitalization. Other outcomes include organ damage/failure, ocular morbidity, and blindness. Restrictive lung disease may develop in patients with SJS and TEN after initial acute pulmonary involvement. Patients with SJS or TEN caused by a drug have a better prognosis the earlier the causative drug is withdrawn.
==== Deep anterior lamellar keratoplasty ==== In this procedure, the anterior layers of the central cornea are removed and replaced with donor tissue. Endothelial cells and the Descemets membrane are left in place. This technique is used in cases of anterior corneal opacifications, scars, and ectatic diseases such as keratoconus.
Astatine is a chemical element; it has symbol At and atomic number 85. It is the rarest naturally occurring element in the Earth's crust, occurring only as the decay product of various heavier elements. All of astatine's isotopes are short-lived; the most stable is astatine-210, with a half-life of 8.1 hours. Consequently, a solid sample of the element has never been seen, because any macroscopic specimen would be immediately vaporized by the heat of its radioactivity. The bulk properties of astatine are not known with certainty. Many of them have been estimated from its position on the periodic table as a heavier analog of fluorine, chlorine, bromine, and iodine, the four stable halogens. However, astatine also falls roughly along the dividing line between metals and nonmetals, and some metallic behavior has also been observed and predicted for it. Astatine is likely to have a dark or lustrous appearance and may be a semiconductor or possibly a metal. Chemically, several anionic species of astatine are known and most of its compounds resemble those of iodine, but it also sometimes displays metallic characteristics and shows some similarities to silver. The first synthesis of astatine was in 1940 by Dale R. Corson, Kenneth Ross MacKenzie, and Emilio G. Segrè at the University of California, Berkeley. They named it from the Ancient Greek ástatos (ἄστατος) 'unstable'. Four isotopes of astatine were subsequently found to be naturally occurring, although much less than one gram is present at any given time in the Earth's crust.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.